熱門資訊> 正文

Genmab reports Q2 Darzalex net sales of $3.54 billion

2025-07-16 18:48

Genmab A/S (GMAB) said Wednesday that net sales of Darzalex in the second quarter of 2025 totaled $3,539 million.
Net trade sales were $2,017 million in the U.S. and $1,521 million in the rest of the world.
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J (JNJ) to develop, manufacture, and commercialize daratumumab.

More on Genmab

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Genmab A/S (GMAB) Q1 2025 Earnings Conference Call Transcript
J&J, Genmab win FDA AdCom backing for multiple myeloma therapy
Seeking Alpha’s Quant Rating on Genmab

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。